Display options
Cite
Berger B, Bachmann F, Duthaler U, et al. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. Front Pharmacol. 2018;9:774doi: 10.3389/fphar.2018.00774.
Berger, B., Bachmann, F., Duthaler, U., Krähenbühl, S., & Haschke, M. (2018). Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. Frontiers in pharmacology, 9774. https://doi.org/10.3389/fphar.2018.00774
Berger, Benjamin, et al. "Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug." Frontiers in pharmacology vol. 9 (2018): 774. doi: https://doi.org/10.3389/fphar.2018.00774
Berger B, Bachmann F, Duthaler U, Krähenbühl S, Haschke M. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. Front Pharmacol. 2018 Jul 24;9:774. doi: 10.3389/fphar.2018.00774. eCollection 2018. PMID: 30087611; PMCID: PMC6066528.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2018 Jul 24;9:774. doi: 10.3389/fphar.2018.00774. eCollection 2018.

Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug.

Frontiers in pharmacology

Benjamin Berger, Fabio Bachmann, Urs Duthaler, Stephan Krähenbühl, Manuel Haschke

Affiliations

  1. Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.
  2. Department of Biomedicine, University of Basel, Basel, Switzerland.
  3. Swiss Center for Applied Human Toxicology (SCAHT), Basel, Switzerland.
  4. Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
  5. Institute of Pharmacology, University of Bern, Bern, Switzerland.

PMID: 30087611 PMCID: PMC6066528 DOI: 10.3389/fphar.2018.00774

Abstract

Metoprolol is used for phenotyping of cytochrome P450 (CYP) 2D6, a CYP isoform considered not to be inducible by inducers of the CYP2C, CYP2B, and CYP3A families such as rifampicin. While assessing CYP2D6 activity under basal conditions and after pre-treatment with rifampicin

Keywords: CYP induction; CYP2D6; metoprolol; phenotyping; α-OH-metoprolol

References

  1. Br J Clin Pharmacol. 1985 Oct;20(4):327-31 - PubMed
  2. Bioorg Med Chem Lett. 2009 Feb 1;19(3):803-6 - PubMed
  3. Clin Pharmacokinet. 2014 Mar;53(3):271-282 - PubMed
  4. Rapid Commun Mass Spectrom. 2007;21(14):2323-31 - PubMed
  5. Eur J Clin Pharmacol. 2007 Apr;63(4):321-33 - PubMed
  6. Drug Metab Dispos. 1996 Mar;24(3):350-5 - PubMed
  7. Br J Clin Pharmacol. 1982 Mar;13(3):387-91 - PubMed
  8. Methods. 2001 Dec;25(4):402-8 - PubMed
  9. Clin Pharmacokinet. 2016 Jan;55(1):79-91 - PubMed
  10. Br J Clin Pharmacol. 2004 Apr;57(4):495-9 - PubMed
  11. J Pharmacol Exp Ther. 2001 Dec;299(3):849-57 - PubMed
  12. J Pharmacol Exp Ther. 1988 Oct;247(1):242-7 - PubMed
  13. Br J Clin Pharmacol. 1986 Jul;22(1):49-53 - PubMed
  14. Front Pharmacol. 2016 Nov 21;7:443 - PubMed
  15. Drug Metab Dispos. 2006 Jan;34(1):75-83 - PubMed
  16. Eur J Clin Pharmacol. 2001 May;57(2):143-6 - PubMed
  17. Clin Pharmacol Ther. 1979 Sep;26(3):326-9 - PubMed
  18. Lancet. 2005 Nov 5;366(9497):1622-32 - PubMed
  19. N Engl J Med. 1982 Dec 16;307(25):1558-60 - PubMed
  20. J Pharmacokinet Biopharm. 1974 Aug;2(4):347-64 - PubMed
  21. Br J Clin Pharmacol. 2004 Sep;58(3):288-97 - PubMed
  22. Br J Clin Pharmacol. 2005 Feb;59(2):199-206 - PubMed
  23. Clin Pharmacokinet. 1980 Nov-Dec;5(6):557-69 - PubMed
  24. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):125-35 - PubMed
  25. Br J Clin Pharmacol. 2008 Oct;66(4):473-84 - PubMed
  26. Clin Pharmacol Ther. 2013 Sep;94(3):394-9 - PubMed
  27. Trends Pharmacol Sci. 1993 Aug;14(8):292-4 - PubMed
  28. Lancet. 1999 Jun 12;353(9169):2001-7 - PubMed
  29. Cell Biol Toxicol. 2012 Apr;28(2):69-87 - PubMed
  30. Drug Metab Dispos. 2003 Apr;31(4):421-31 - PubMed
  31. Chem Res Toxicol. 2003 Apr;16(4):450-9 - PubMed
  32. Lancet. 1999 Nov 20;354(9192):1751-6 - PubMed
  33. Br J Clin Pharmacol. 1985 Dec;20(6):555-66 - PubMed

Publication Types